Travere Therapeutics (TVTX) Asset Writedowns and Impairment (2015 - 2022)
Travere Therapeutics posted quarterly Asset Writedowns and Impairment of -$1.0 million for Q4 2022, down 17.96% year-on-year from -$1.3 million in Q4 2021, and down 413.37% on a QoQ basis from $329000.0 in Q3 2022.
Travere Therapeutics (TVTX) has 7 years of Asset Writedowns and Impairment data on file, last reported at -$1.0 million in Q4 2022.
- For the quarter ending Q4 2022, Asset Writedowns and Impairment fell 17.96% year-over-year to -$1.0 million; the trailing twelve-month figure through Dec 2022 stood at $1.0 million (up 108.63% YoY), and the FY2025 full-year result was $684000.0, down 75.74% from the prior year.
- Asset Writedowns and Impairment for Q4 2022 stood at -$1.0 million, down from $329000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $25.5 million in Q1 2019 and bottomed at -$24.0 million in Q4 2019.
- The 4-year median for Asset Writedowns and Impairment is $475000.0 (2021), against an average of $475454.5.
- The widest annual swing landed in 2020, when Asset Writedowns and Impairment soared 109.26%; it then plunged 139.28% in 2021.
- A 4-year view of Asset Writedowns and Impairment shows it stood at -$24.0 million in 2019, then surged by 109.26% to $2.2 million in 2020, then slumped by 139.28% to -$874000.0 in 2021, then retreated by 17.96% to -$1.0 million in 2022.
- The last three Asset Writedowns and Impairment figures came in at -$1.0 million (Q4 2022), $329000.0 (Q3 2022), and $792000.0 (Q2 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -1.03 Mn |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | 329,000.00 |
| Sep 30, 2022 | 329,000.00 |
| Jun 30, 2022 | 792,000.00 |
| Jun 30, 2022 | 792,000.00 |
| Mar 31, 2022 | 949,000.00 |
| Mar 31, 2022 | 949,000.00 |
| Dec 31, 2021 | -874,000.00 |
| Dec 31, 2021 | -874,000.00 |
| Sep 30, 2021 | 410,000.00 |
| Sep 30, 2021 | 410,000.00 |
| Jun 30, 2021 | 475,000.00 |
| Jun 30, 2021 | 475,000.00 |
| Mar 31, 2021 | 487,000.00 |
| Mar 31, 2021 | 487,000.00 |
| Dec 31, 2020 | 2.23 Mn |
| Dec 31, 2020 | 2.23 Mn |
| Dec 31, 2019 | -24.03 Mn |
| Dec 31, 2019 | -24.03 Mn |
| Mar 31, 2019 | 25.50 Mn |
| Mar 31, 2019 | 25.50 Mn |
| Sep 30, 2017 | -410,000.00 |
| Sep 30, 2017 | -410,000.00 |
| Dec 31, 2016 | -58,000.00 |
| Dec 31, 2016 | -58,000.00 |
| Sep 30, 2016 | 9,000.00 |
| Sep 30, 2016 | 9,000.00 |
| Sep 30, 2015 | 4.70 Mn |
| Sep 30, 2015 | 4.70 Mn |